Introduction
Disorders of fibrinogen (Fg) are usually the result of genetic mutations that hesitate in reduced levels of protein (hypofibrinogenemia) or in an abnormal molecule (dysfibrinogenemia).
1-3 However, plasma factors or microenvironment can determine an acquired defect of Fg. 4, 5 Our goal is to identify the cause of coagulopathy in a 65-year-old man, diagnosed because of a discrepancy between immunological Fg and functional Fg.
Case Report
An apparently healthy 65-year-old man without a tendency to bleed was referred to our center because of abnormal coagulation assay results (►Table 1) that were detected prior to surgery for thyroid nodule. He had never received any anticoagulants. Hereditary deficit was excluded, due to normal coagulation assays tested a year ago. Patient never showed thrombotic or hemorrhagic diseases. Thyroid nodule was removed without any bleeding problems during or after the procedure. At present, the patient is healthy and asymptomatic.
Coagulation Assays
Routine coagulation screening revealed unmeasurable activated partial thromboplastin time (aPTT), prothrombin time 
Inhibitor Detection and Characterization
The patient was screened for monoclonal gammopathy. The band of monoclonal light chain k was identified near the band of Fg on plasma immunofixation (►Fig. 1).
No clonality was identified on urine and serum immunofixation, possibly because k chains were bound to Fg molecules, absent in serum assay. Bone marrow plasma cells (PCs) were normal (4-5%) but 80% of these PCs were monoclonal on flow cytometric assay (CD138þ, CD38þ, CD19À, 93.6/ 5.9% k/lambda intracytoplasmatic ratio).
Treatment with dexamethasone (40 mg/day for 4 days) resulted in an almost complete correction of functional Fg
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value, and normalization of aPTT, PT, and TT values. After steroid treatment, free light chain (FLC) k values rose as if k light chains were released from Fg molecules. Three months after steroid therapy, aPTT, PT, and TT became abnormal again (prolonged aPTT and PT, unmeasurable TT), along with unmeasurable functional Fg values.
To better understand the inhibitory effect observed on patient's functional Fg, we performed three mixed assays.
• We screened 20 patients with multiple myeloma (control group) for similarities with this patient's coagulopathy: in four patients we found TT elongation but normal functional Fg values. Plasma immunofixation performed in these four myeloma patients did not reveal a light chain band that run at the same level of Fg molecules. A mixing test with purified Fg from the multiple myeloma patients and Fg purified from PNP did not show any decrease in measured functional Fg values of the mix sample.
Discussion
Interactions of paraprotein with fibrinopeptide release, fibrin polymerization, or factor XIIIa-mediated cross-linking have already been described. Paraprotein may impair fibrin formation by either antigen-antibody interactions, nonspecific interactions, or increasing plasma viscosity caused by high protein concentration in the blood. This case is particularly unusual because the inhibitory effect on Fg molecules was induced by a single light chain rather than by a complete antibody molecule. There have been described only two previous reports of a light chain inhibitory effect on Fg.
8,9
A specific test to assay the interaction between monoclonal light chain (obtained from patient's plasma) and Fg from PNP will be necessary to surely prove coagulopathy related to monoclonal FLCs. Kotlín et al described a case of myeloma paraprotein immunoglobulin G interfering with fibrin polymerization: enzyme-linked immunosorbent assay (ELISA) and Western blotting experiments confirmed the antibody-antigen interaction of paraprotein with Fg. 10 The normalization of coagulation assays occurred after melphalan-prednisone treatment as in our patient after dexamethasone treatment.
In our patient we could exclude an antibody-antigen interaction because a single light chain is involved. No alterations in platelet aggregation test were observed, so an interaction at the Fg's binding site for platelets IIb/IIIa glycoprotein was excluded.
As no hemorrhagic events were reported by the patient, an interaction at the Fg's binding site for coagulation factor XIII (fXIII) or a fibrinopeptide A (FpA) impaired release was unlikely.
We suspect an interference with fibrinopeptide B release or fibrin polymerization.
Three months after steroid therapy, aPTT and PT were abnormal but measurable, while TT and functional Fg were unmeasurable. Moreover, PT and aPTT mixing test with normal plasma (1:1) resulted in PT and aPTT correction, while functional Fg was still unmeasurable (mixing assay 1). Therefore, the PT and aPTT tests are less sensitive than the TT test and functional Fg assay. Considering the above, the inhibitory agent present in the patient plasma may be low titer, even if we did not measure it directly. We could only measure FLC k values, which were inversely related to the inhibitory effect on functional Fg (after steroid treatment FLC k values rose, while functional Fg increased).
This case is interesting because studying coagulation assays allowed us to diagnose FLC-MGUS (monoclonal gammopathy of undetermined significance), which needs to be followed up.
